Details of the Drug Reposition

General Information of This Drug (ID: DMUL8ZT)

Drug Name
SHR0302   DMUL8ZT
Synonyms
Ivarmacitinib; SHR0302; 1445987-21-2; Ivarmacitinib [USAN]; SHR0302 base; UNII-K6K4B9Z5TV; K6K4B9Z5TV; (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; rel-(3aR,5s,6aS)-N-(3-Methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; SHR-0302; IVARMACITINIB [INN]; SHR0302 FREE BASE; SHR-0302 FREE BASE; CHEMBL5095398; SCHEMBL15077696; SCHEMBL15077710; SCHEMBL16191633; GTPL11878; EX-A5101; WHO 11823; AKOS040759719; NCGC00687790-01; AC-36766; example 34 [WO2013091539A1]; MS-27180; HY-112724; CS-0062969; F82248; US9527851, 34; US9527851, 74; (3AR,5S,6AS)-N-(3-METHOXY-1,2,4-THIADIAZOL-5-YL)-5-(METHYL (7H-PYRROLO(2,3- D)PYRIMIDIN-4-YL)AMINO) HEXAHYDROCYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE; (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl (7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino) hexahydrocyclopenta(c)pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; CYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE, HEXAHYDRO-N-(3-METHOXY-1,2,4- THIADIAZOL-5-YL)-5-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-, (3A.ALPHA.,5.ALPHA.,6A.ALPHA.)-; Cyclopenta(c)pyrrole-2(1H)-carboxamide, hexahydro-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3aalpha,5alpha,6aalpha)-
Drug Type
Small molecule
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ulcerative colitis DIS8K27O DD71 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Crohn disease DIS2C5Q8 DD70 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05181137) A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT03677648) A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease. U.S.National Institutes of Health.